Tilray Brands shares fell to a new 52-week low after the U.S. Drug Enforcement Administration (DEA) temporarily paused a hearing on potential cannabis rescheduling. The pause added to regulatory uncertainty in the U.S. market and weighed on the broader cannabis sector, including major players such as Tilray. Tilray’s stock has declined more than 23% recently amid the news.
The drop comes a week before Tilray reports first-quarter fiscal 2027 results on October 8. Its previous quarterly results showed record revenue, supported by international sales and acquisitions. Ongoing regulatory questions in the key U.S. market remain a primary concern for investors.